⚠️
Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Elevated cost per beneficiary
Risk indicators are statistical patterns, not allegations. Learn more
8,728
Total Claims
$5.5M
Drug Cost
953
Beneficiaries
$5,778
Cost/Patient
Risk Score Breakdown 3/100
Low (0)Moderate (15)Elevated (30)High (50+)
Cost per patient outlier+3
Score components are additive. Read full methodology
Peer Comparison vs. 6,382 Endocrinology providers
+47%
Cost per patient vs peers
$5,778 vs $3,933 avg
+12%
Brand preference vs peers
57.1% vs 51.2% avg
Brand vs Generic
43% generic
Brand: 4,591 claims · $5.3M
Generic: 3,451 claims · $99K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Dulaglutide | 438 | $878K |
| Empagliflozin | 386 | $530K |
| Sitagliptin Phosphate | 430 | $494K |
| Semaglutide | 278 | $477K |
| Insulin Aspart | 264 | $303K |
| Insulin Lispro | 179 | $252K |
| Insulin Glargine,hum.Rec.Anlog | 265 | $249K |
| Dapagliflozin Propanediol | 185 | $247K |
| Insulin Aspart | 133 | $232K |
| Canagliflozin | 147 | $219K |
| Insulin Degludec | 141 | $126K |
| Liraglutide | 51 | $113K |
| Insulin Lispro | 76 | $106K |
| Insulin Glargine,hum.Rec.Anlog | 139 | $103K |
| Exenatide Microspheres | 49 | $102K |
Prescribing Profile
Patient Profile
70
Avg Age
62%
Female
1.91
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About